Search
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnSertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was f...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMianserin
go.drugbank.com/drugs/DB06148ApprovedWithdrawnA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAcetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigationalAcetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. Ac...
Nylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impair...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 re...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGarenoxacin
go.drugbank.com/drugs/DB06160ExperimentalGarenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsAsenapine
go.drugbank.com/drugs/DB06216ApprovedInvestigationalDeveloped by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also be...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTolperisone
go.drugbank.com/drugs/DB06264InvestigationalTolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesUdenafil
go.drugbank.com/drugs/DB06267ApprovedUdenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates